Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

October 24, 2018

Study Completion Date

October 24, 2018

Conditions
Cancer
Interventions
DRUG

Ranitidine

Thirty subjects will receive Ranitidine to a maximum of 900 mg/day in 2 daily oral doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets.

Trial Locations (1)

B3H 1V7

Nova Scotia Health Authority, Halifax

All Listed Sponsors
collaborator

Dalhousie University

OTHER

lead

Nova Scotia Health Authority

OTHER

NCT03145012 - Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity | Biotech Hunter | Biotech Hunter